STOCK TITAN
  1. Home
  2. News
  3. EVGN

EVOGENE LTD. - EVGN STOCK NEWS

Welcome to our dedicated page for EVOGENE LTD. news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on EVOGENE LTD. stock.

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a leading computational biology company leveraging big data and artificial intelligence to revolutionize the development of life-science-based products. The company, headquartered in Rehovot, Israel, employs cutting-edge technologies to increase the probability of success while reducing development time and cost across multiple market segments including human health, agriculture, and industrial applications. Evogene has established three unique tech-engines - MicroBoost AI, ChemPass AI, and GeneRator AI - each focused on products based on microbes, small molecules, and genetic elements respectively.

The company operates through several subsidiaries that utilize these tech-engines:

  • Biomica Ltd.: Develops microbiome-based therapeutics for diseases such as antibiotic-resistant bacteria, cancer, and gastrointestinal disorders.
  • Lavie Bio Ltd.: Focuses on microbiome-based ag-biologicals to enhance crop yield and sustainability.
  • AgPlenus Ltd.: Innovates in sustainable crop protection products.
  • Canonic Ltd.: Develops medical cannabis products.
  • Casterra Ag Ltd.: Produces high-yield castor seeds for biofuels and other industrial uses.

Evogene's recent achievements include securing new seed production agreements for Casterra, advancing clinical trials for Biomica's immuno-oncology candidate BMC128, and extending validation trials for Lavie Bio's biofungicides in collaboration with Bayer AG. Evogene has been proactive in addressing its Nasdaq listing compliance and continues to prioritize innovation through strategic partnerships and collaborative ventures. For more information, please visit www.evogene.com.

News

Evogene Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) Announces Q3 2023 Financial Results and Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
earnings
-
News

Lavie Bio Reports Advancement in Bio-Fungicide Program Against Downy Mildew with 2023 Field Trial Results

Rhea-AI Summary
EVGN: Lavie Bio's LAV321 Bio-Fungicide Shows Promising Results in 2023 Field Trials, Protecting Against Downy Mildew and Late Blight Diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
News

Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023

Rhea-AI Summary
Evogene Ltd. will release its financial results for Q3 2023 on November 15, 2023. The company aims to revolutionize life-science product discovery and development. A conference call will be held on the same day at 9:00 AM ET to discuss the results. The call can be joined using the provided numbers. A replay of the call will be available for three days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
earnings
News

Colors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology

Rhea-AI Summary
Colors Farm, Evogene, and Ben-Gurion University have announced a collaboration to develop gene editing technology for crustaceans. The project aims to enhance traits such as growth rate, disease resistance, and environmental adaptation in giant freshwater prawn, white leg shrimp, and red swamp crayfish. The initiative has received a grant from the Israel Innovation Authority. The global shrimp market is predicted to reach US$88 billion by 2028 with a CAGR of 4.7%, while the crayfish market is expected to grow at a CAGR of 31.5% from 2024-2032. This collaboration aims to meet the rising demand for seafood and sustainable aquaculture practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
News

Evogene Provides Operational Update Amidst Current Security Situation in Israel

Rhea-AI Summary
Evogene provides an update to investors and stakeholders amidst the ongoing security situation in Israel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.55%
Tags
none
-
News

Casterra Delivers First Shipment of Castor Seeds to Africa

Rhea-AI Summary
Casterra Ag Ltd. has announced the shipment of its first batch of high-yield, high-oil castor seeds valued at US$1 million. This is part of a framework agreement with a world-leading oil and gas company, with US$11.3M purchase orders. The seeds have a germination percentage rate of 90%, exceeding industry standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
News

Evogene Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Evogene Ltd. announces financial results for Q2 2023, highlighting achievements and partnerships. Evogene secures $8.5M investment, receives purchase orders worth $11.3M, and closes $20M financing round for Biomica. Lavie Bio enters licensing agreement with Corteva for $5M upfront payment. AgPlenus appoints Dr. Adrian Percy to board of directors. Evogene reports consolidated cash of $33.9M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.23%
Tags
earnings
-
News

Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center

Rhea-AI Summary
Biomica Ltd., a clinical-stage biopharmaceutical company, has opened a second site at The Davidoff Cancer Center for its Phase I clinical trial of immuno-oncology drug candidate BMC128. The trial aims to assess the safety and tolerability of BMC128 in combination with Bristol Myers Squibb's Opdivo® for refractory patients with NSCLC, melanoma, or RCC. The Davidoff Center is a renowned comprehensive cancer center in Israel. Biomica's CEO expressed pride in the milestone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
-
News

Evogene Schedules Second Quarter 2023 Financial Results Release & Conference Call for August 17, 2023

Rhea-AI Summary
Evogene Ltd. (EVGN) to Release Q2 2023 Financial Results and Host Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
earnings
News

Evogene's ChemPass AI Tech-Engine is Introduced with New Breakthrough Machine Learning Technology for Target-Protein Discovery

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
AI

FAQ

What is the current stock price of EVOGENE LTD. (EVGN)?

The current stock price of EVOGENE LTD. (EVGN) is $1.68 as of November 18, 2024.

What is the market cap of EVOGENE LTD. (EVGN)?

The market cap of EVOGENE LTD. (EVGN) is approximately 9.3M.

What does Evogene Ltd. do?

Evogene Ltd. is a computational biology company that uses AI and big data to develop life-science-based products in human health, agriculture, and industrial applications.

Where is Evogene Ltd. headquartered?

Evogene Ltd. is headquartered in Rehovot, Israel.

What are Evogene's main technology platforms?

Evogene has three main tech-engines: MicroBoost AI for microbes, ChemPass AI for small molecules, and GeneRator AI for genetic elements.

Who are some of Evogene's subsidiaries?

Evogene's subsidiaries include Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., Canonic Ltd., and Casterra Ag Ltd.

What is the focus of Biomica Ltd.?

Biomica Ltd. focuses on developing microbiome-based therapeutics for diseases such as antibiotic-resistant bacteria, cancer, and gastrointestinal disorders.

What recent partnerships has Evogene engaged in?

Evogene recently extended validation trials for Lavie Bio's biofungicides with Bayer AG, and secured new seed production agreements for Casterra.

How is Evogene addressing its Nasdaq listing compliance?

Evogene is actively working to regain compliance with Nasdaq's listing requirements and considers various options, including reverse share splits, to maintain its listing.

What are some recent achievements of Evogene Ltd.?

Evogene has advanced clinical trials for Biomica's BMC128, secured new seed production agreements for Casterra, and extended biofungicide validation trials with Bayer AG.

Where can I find more information about Evogene Ltd.?

More information about Evogene Ltd. can be found on their official website at www.evogene.com.

What market segments does Evogene target?

Evogene targets human health, agriculture, and industrial applications through its computational biology platforms and subsidiaries.

Stock EVGN logo
EVOGENE LTD.

Nasdaq:EVGN

EVGN Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

EVGN Stock Data

9.28M
5.37M
1.66%
7.87%
0.5%
Biotechnology
Healthcare
Link
United States of America
Rehovot